Positive Phase IIb Topline Clinical Data For Celgene Oral Compound Apremilast (CC-10004) Reported For Patients With Moderate-to-Severe Psoriasis
Celgene Corporation (NASDAQ:CELG) announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo…
Also tagged Celg, Double Blind Placebo, Nasdaq, Oral Compound, Phase Iib, Psor, Psoriasis
